2022 MRM Talks: Dr. Jean-Sébastien Delisle and Dr. Luis Alberto Perez-Quintero
The MRM Network presents: the MRM Talks. Join us every fourth Thursday at noon to learn more about stem cells and regenerative medicine. The webinar series will feature leading scientists in the field, including MRM Principal Investigators and external guest speakers.
For each seminar, we will also highlight the work of one MRM Trainee, who will present alongside our guest speaker.
In this edition of the MRM Talks:
Dr. Jean-Sébastien Delisle,
Associate Professor, Université de Montréal
Medical Director, Centre d’excellence en thérapie cellulaire (CETC), Hôpital Maisonneuve-Rosemont
Director, ThéCell Network
“Engineering immunity ex vivo; the good, the bad and the ugly”
Dr. Luis Alberto Perez-Quintero,
Research Associate in Prof. Michel Tremblay’s Lab,
“Tackling T cell dysfunction in adoptive cell therapy by targeting phosphatases”
THURSDAY, November 24, 2022
12:00 – 1:00 PM
Missed the presentation? You can catch up on our Youtube Channel.
About the speakers:
After completing his medical and hematology training in 2004 at McGill University, and his Ph.D. in biomedical sciences at the Université de Montréal in 2010, Dr. Delisle focused his research on T-cell biology and human T-cell adoptive therapy. He now leads a basic and translational research program in T-cell immunotherapy at Hôpital Maisonneuve-Rosemont, where he also works as staff hematologist and as Medical director of the Centre of Excellence for Cellular Therapy (CECT), a hospital-based good manufacturing practice (GMP) cell processing facility. Dr. Delisle is an FRQS clinician-scientist scholar (senior) and associate professor at the Université de Montréal.
Dr. Delisle led the development and implementation of several T-cell manufacturing protocols that have been used in early clinical trials. These efforts yielded the first adoptive immunotherapy study in Canada to treat or prevent Epstein-Barr virus-related lymphoma, and blood cancer relapse following hematopoietic cell transplantation through the targeting of newly identified transplantation antigens. His current work includes the translation of processes involving genetically modified T cells and immunomonitoring. This pipeline is supported by Dr. Delisle’s focus on basic T-cell immunology, particularly on therapeutically actionable mechanisms governing T-cell priming, differentiation, and dysfunction that can be leveraged to improve adoptive immunotherapy using ex vivo expanded T cells.
Dr. Luis Alberto Perez-Quintero is a physician who graduated in Colombia and did his master’s and Ph.D. degrees in the laboratory of Dr. Andre Veillette at the Montreal Clinical Research Institute (IRCM) on the study of SLAM family signaling in natural killer (NK) cells. He then did a brief postdoctoral fellowship at the Research Center of the Centre Hospitalier de l’Université de Montréal (CR-CHUM) in neuroimmunology after which he moved to Dr. Tremblay’s lab to study the effects of phosphatase inhibition on the immune system, more specifically in CD8 cytotoxic T cells. His presentation will be on his recent work on that matter.
We want to hear from you, and we welcome your suggestions for speakers!
If you are interested in hosting an invited speaker, please get in touch with us.